Trevi Therapeutics (TRVI) Operating Expenses (2018 - 2022)

Trevi Therapeutics' Operating Expenses history runs 8 years deep, the most recent figure standing at $10.2 million for Q4 2025.

• In Q4 2025, Operating Expenses fell 16.52% year-over-year to $10.2 million; the TTM figure through Mar 2026 stood at $37.9 million (down 4.44% YoY), while the FY2025 annual figure was $49.3 million, down 4.26% from the prior year.
• Operating Expenses for Q4 2025 stood at $10.2 million, down from $13.9 million in the prior quarter.
• The five-year high for Operating Expenses was $14.1 million in Q3 2024, with the low at $6.7 million in Q4 2022.
• The 5-year median for Operating Expenses is $8.9 million (2023), against an average of $9.8 million.
• The sharpest annual moves came in 2022 and 2024: Operating Expenses retreated 19.53% in 2022, then soared 58.54% in 2024.
• Trevi Therapeutics' Operating Expenses stood at $8.3 million in 2021, then decreased by 19.53% to $6.7 million in 2022, then surged by 34.19% to $8.9 million in 2023, then surged by 37.05% to $12.2 million in 2024, then decreased by 16.52% to $10.2 million in 2025.
• Business Quant data shows TRVI's Operating Expenses at $10.2 million in Q4 2025, $13.9 million in Q3 2025, and $13.7 million in Q2 2025.